rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2012-8-1-68-74rpcardio-418Research ArticleNOTES FROM PRACTICEКЛИНИЧЕСКИЙ ОПЫТEFFICACY OF FIXED COMBINATION OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN COMPLEX THERAPY OF THE PATIENT OF VERY HIGH CARDIOVASCULAR RISKЭФФЕКТИВНОСТЬ ФИКСИРОВАННОЙ КОМБИНАЦИИ ВАЛСАРТАНА, АМЛОДИПИНА И ГИДРОХЛОРОТИАЗИДА В КОМПЛЕКСНОЙ ТЕРАПИИ ПАЦИЕНТА ОЧЕНЬ ВЫСОКОГО КАРДИОВАСКУЛЯРНОГО РИСКАСоколовИ. М.SokolovI. M.

д.м.н., профессор кафедры факультетской терапии лечебного факультета

docsim@bk.ruЖелезняковаН. А.ZheleznyakovaN. A.

к.м.н., ассистент кафедры факультетской терапии лечебного факультета

Саратовский Государственный Медицинский Университет им В.И. РазумовскогоРоссияSaratov State Medical University named after V.I. RazumovskiiRussian Federation201227122015816874Copyright © Sokolov I.M., Zheleznyakova N.A., 20152015Соколов И.М., Железнякова Н.А.Sokolov I.M., Zheleznyakova N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/418

The high prevalence of arterial hypertension in association with high and very high cardiovascular risk requires widespread use of combined therapy. Current approaches to selection of combination components of antihypertensive drugs are based the efficacy of these drugs proven in multicenter randomized clinical trials. The triple combination of calcium antagonist, angiotensin II receptor blocker and thiazide diuretic is regarded as the best option for combined therapy in patients with arterial hypertension and ischemic heart disease to reduce cardiovascular risk.

Высокая распространённость артериальной гипертонии в сочетании с высоким и очень высоким сердечно-сосудистым риском определяют необходимость широкого применения комбинированной терапии. Современные подходы к выбору компонентов комбинации антигипертензивных средств опираются на эффективность последних, показанную в многоцентровых рандомизированных клинических испытаниях. Тройная комбинация антагониста кальция, блокатора рецепторов ангиотензина II и тиазидного диуретика рассматривается в качестве оптимального варианта терапии пациентов при сочетании артериальной гипертонии и ишемической болезни сердца для снижения кардиоваскулярного риска.

фиксированная комбинациявалсартанамлодипингидрохлоротиазидстенокардияартериальная гипертонияfixed combinationvalsartanamlodipinehydrochlorothiazideanginaarterial hypertensionReferencesShal'nova S.A., Balanova Yu.A., Konstantinov V.V. i dr . Hypertension: Prevalence, awareness, taking antihypertensive medication and treatment efficacy in the population of the Russian Federation. Rossiyskiy kardiologicheskiy zhurnal 2006; (4): 45–50. Russian (Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006; (4): 45–50).Shal'nova S.A., Balanova Yu.A., Konstantinov V.V. i dr . Hypertension: Prevalence, awareness, taking antihypertensive medication and treatment efficacy in the population of the Russian Federation. Rossiyskiy kardiologicheskiy zhurnal 2006; (4): 45–50. Russian (Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006; (4): 45–50).National guidelines for diagnosis and treatment of hypertension. Kardiovaskulyarnaya Terapiya i Profilaktika 2008; 7(6) suppl 2: 1-31. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная Терапия и Профилактика 2008; 7(6) Приложение 2: 1-31).National guidelines for diagnosis and treatment of hypertension. Kardiovaskulyarnaya Terapiya i Profilaktika 2008; 7(6) suppl 2: 1-31. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная Терапия и Профилактика 2008; 7(6) Приложение 2: 1-31).Avoiding Cardiovascular Events through COMbination Therapy In Patients Living with Systolic Hypertension N Engl J Med 2008; 359: 2417-2428.Avoiding Cardiovascular Events through COMbination Therapy In Patients Living with Systolic Hypertension N Engl J Med 2008; 359: 2417-2428.Deanfield J., Detry J., Lichtlen P . et al. Amlodipine reduces transient myocardial ischemia in patients with coronary heart disease: Double-blind Circadian Anti-ischemia Program in Europe (CAPE trial). JACC 1994; 26 (4): 1460—1467.Deanfield J., Detry J., Lichtlen P . et al. Amlodipine reduces transient myocardial ischemia in patients with coronary heart disease: Double-blind Circadian Anti-ischemia Program in Europe (CAPE trial). JACC 1994; 26 (4): 1460—1467.Jorgensen B., Thaulow E. Effects of amlodipine on ischemia after percutaneuos transluminal coronary angioplasty: Secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) study. Am Heart J 2003; 145: 1030—1035.Jorgensen B., Thaulow E. Effects of amlodipine on ischemia after percutaneuos transluminal coronary angioplasty: Secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) study. Am Heart J 2003; 145: 1030—1035.Packer M., O'Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107—1114.Packer M., O'Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107—1114.Mancini G.B.J., Miller M.E., Evans G.W. et al. Post hoc analysis of coronary findings from the Prospective Randomized Evaluation of the Vascular Effects of the Norvasc Trial (PREVENT). Am J Cardiol 2002; 89 (12): 1414—1416.Mancini G.B.J., Miller M.E., Evans G.W. et al. Post hoc analysis of coronary findings from the Prospective Randomized Evaluation of the Vascular Effects of the Norvasc Trial (PREVENT). Am J Cardiol 2002; 89 (12): 1414—1416.Nissen S.E., Tuzcu E.M., Libby P . et al. The CAMELOT/NORMALISE study. JAMA 2004; 18: 2217–2226.Nissen S.E., Tuzcu E.M., Libby P . et al. The CAMELOT/NORMALISE study. JAMA 2004; 18: 2217–2226.Liebson P ., Grandits G, Dianzumba S. et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 1995;91:698-706.Liebson P ., Grandits G, Dianzumba S. et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 1995;91:698-706.Kloner R.A., Sowers J.R. Amiodipine cardiovascular community trial. Am J Cardiol 1996; 77: 713- 722.Kloner R.A., Sowers J.R. Amiodipine cardiovascular community trial. Am J Cardiol 1996; 77: 713- 722.The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967—1975.The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967—1975.Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2022–2031.Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2022–2031.Dahlof B., Sever P .S., Poulter N.R. et al. Prevention of cardiovascular events with an anti-hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (AS-COT–BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.Dahlof B., Sever P .S., Poulter N.R. et al. Prevention of cardiovascular events with an anti-hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (AS-COT–BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.Val-HeFT Maggioni A.P ., Latini R., Carson P .E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val–HeFT). Am Heart J 2005; 149: 548–57.Val-HeFT Maggioni A.P ., Latini R., Carson P .E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val–HeFT). Am Heart J 2005; 149: 548–57.Viberti G. Microalbuminuria Reduction With Valsartan in Patients With T ype 2 Diabetes Mellitus: A Blood Pressure – Independent Effect. Wheeldon and for the Microalbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Circulation 2002; 106: 672–678.Viberti G. Microalbuminuria Reduction With Valsartan in Patients With T ype 2 Diabetes Mellitus: A Blood Pressure – Independent Effect. Wheeldon and for the Microalbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Circulation 2002; 106: 672–678.The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients with Type 2 Diabetes. Diabetes Care 2007:30(6):1581–1583.The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients with Type 2 Diabetes. Diabetes Care 2007:30(6):1581–1583.Peters S., Gotting B., Trummel M. et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL–PREST trial. J Invasive Cardiol 2001; 13: 93–97.Peters S., Gotting B., Trummel M. et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL–PREST trial. J Invasive Cardiol 2001; 13: 93–97.Peters S., Trummel M., Meyners W. et al. Valsartan versus ACE inhibition after bare metal stent im- plantation–results of the VALVACE trial. Int J Cardiol 2005; 98: 331–335Peters S., Trummel M., Meyners W. et al. Valsartan versus ACE inhibition after bare metal stent im- plantation–results of the VALVACE trial. Int J Cardiol 2005; 98: 331–335Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2022–2031.Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2022–2031.McMurray J., Solomon S., Pieper K. et al. The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006;47:726 –733.McMurray J., Solomon S., Pieper K. et al. The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006;47:726 –733.Mochizuki S., Dahl B., Shimizu M. et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431 -1439.Mochizuki S., Dahl B., Shimizu M. et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431 -1439.Sawada T., Takahashi T., Yamada H. et al. for the KYOTO HEART Study Group. Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events. J Hum Hypertens 2008; 1–8.Sawada T., Takahashi T., Yamada H. et al. for the KYOTO HEART Study Group. Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events. J Hum Hypertens 2008; 1–8.Karpov Yu.A., Chazova I.E., Vigdorchik A.V. on behalf of the research team. Efficacy and safety of fixed combination of amlodipine and valsartan in the treatment of hypertension in clinical practice: results of observational study of the Russian EXTRA-2. Sistemnye gipertenzii 2010; 4:14–20. Russian (Карпов Ю.А., Чазова И.Е., Вигдорчик А.В. от лица исследовательской группы. Эффективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Системные гипертензии 2010; 4:14–20).Karpov Yu.A., Chazova I.E., Vigdorchik A.V. on behalf of the research team. Efficacy and safety of fixed combination of amlodipine and valsartan in the treatment of hypertension in clinical practice: results of observational study of the Russian EXTRA-2. Sistemnye gipertenzii 2010; 4:14–20. Russian (Карпов Ю.А., Чазова И.Е., Вигдорчик А.В. от лица исследовательской группы. Эффективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Системные гипертензии 2010; 4:14–20).

The authors declare that there are no conflicts of interest present.